Successful use of a second course of caplacizumab in relapsed thrombotic thrombocytopenic purpura.

There is limited data on the use of caplacizumab beyond the initial treatment course. We describe a patient case demonstrating the efficacy of a second course of caplacizumab in a patient with relapsed acquired thrombotic thrombocytopenic purpura (TTP). A 25-year-old female was treated for an initial event of TTP with steroids, plasma exchange, rituximab, and caplacizumab. Caplacizumab was continued 30 days post plasma exchange, which was on day 46 of treatment, at which time platelets had improved to 292 x 10